SAM
ALNY icon

Sherman Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Sherman Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.51K Hold
15
– – ﹤0.01% 128
2026
Q1 		$4.96K Hold
15
– – ﹤0.01% 142
2025
Q4 		$5.96K Hold
15
– – 0.01% 138
2025
Q3 		$6.84K Hold
15
– – 0.01% 135
2025
Q2 		$4.89K Hold
15
– – ﹤0.01% 138
2025
Q1 		$4.05K Hold
15
– – ﹤0.01% 141
2024
Q4 		$3.53K Buy
+15
New +$3.94K ﹤0.01% 141

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sherman Asset Management's ALNY Position: Q2 2026 in Review

Sherman Asset Management held its Alnylam Pharmaceuticals (ALNY) position steady in Q2 2026 at 15 shares worth $4.51K. The position accounts for ﹤0.01% of the portfolio, ranked #128.

Sherman Asset Management first reported a position in ALNY in Q4 2024 and has held it in 7 quarters since. The position peaked at $6.84K in Q3 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Sherman Asset Management held 15 shares of Alnylam Pharmaceuticals worth $4.51K as of Q2 2026.
  • Sherman Asset Management left its Alnylam Pharmaceuticals share count unchanged in Q2 2026.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Sherman Asset Management's portfolio in Q2 2026, its #128 holding.
  • Sherman Asset Management first reported a position in Alnylam Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • Sherman Asset Management's Alnylam Pharmaceuticals position peaked at $6.84K in Q3 2025.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Sherman Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.